Preparing for China · patient guide

Pathology review for lung cancer before treatment in China

A pathology review for lung cancer asks a second group of pathologists to re-examine your existing biopsy slides and tissue blocks and compare their findings with your original report. It can clarify the tumour type, check whether the material is adequate for molecular testing, and resolve points that affect treatment planning. It does not by itself confirm hospital acceptance, eligibility for a trial, or which treatment you will receive; the treating team decides those after reviewing the full case.

Go to the practical guidance ↓
AI illustration: A tidy desk with a notebook, pen, folder, pen holder, potted plant, and books near a window.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

What a lung cancer pathology review actually changes

Pathology sits underneath almost every lung cancer decision. Before surgery, radiotherapy or a drug treatment, the clinical team needs to know what kind of cancer it is, whether the sample is adequate, and whether the features that guide treatment have been reported. A review is a fresh look at the same material by pathologists who did not produce the first report. It is not a new biopsy and it does not replace your oncologist's assessment.

The most useful reviews answer a specific question. Common examples include confirming the histological type when the original report is ambiguous, checking whether a small biopsy gives enough tissue for the molecular tests the treating team wants, or reconciling two reports that disagree. Sometimes the review confirms the original findings, which is itself useful: it tells you the plan rests on a checked diagnosis. Sometimes it changes the classification or adds information, and the treating team then decides what that means for your options.

A review is also not a treatment plan. The pathologist describes what the tissue shows. Whether that points to surgery, radiotherapy, targeted therapy, immunotherapy or a combination is a decision for the oncology and thoracic team, based on staging, your general health and your own priorities. Keep those two steps separate when you plan.

Related treatment reference

The material a reviewing pathologist needs

A review is only as good as the material supplied. The reviewing laboratory generally needs the original stained slides and, where possible, the paraffin tissue blocks from which they were cut. Blocks matter because they allow new sections to be cut and additional tests to be run if the review raises a question. If blocks cannot leave your hospital, ask whether unstained slides can be provided instead, and how many.

The original pathology report is essential, including any addenda and molecular reports. A report that says only "non-small cell lung cancer" gives the reviewer less to work with than one that states the subtype, the grade where applicable and the tests already performed. If molecular testing was done, send those reports too, because the review may need to judge whether the results are reliable or whether the tissue is exhausted.

Imaging and clinical summaries help the pathologist interpret the sample in context, but they do not substitute for tissue. A short summary of the clinical question, in English or with translation, prevents the review from answering the wrong question. Ask the receiving pathology service what it requires in terms of slide numbers, block handling and courier arrangements before anything is shipped.

  • Original H&E and any special-stain slides
  • Paraffin blocks, or unstained slides if blocks cannot be released
  • The full original pathology report with addenda
  • Any molecular or genomic test reports already issued
  • A brief clinical summary and the specific question you want answered

Questions to settle before sending slides abroad

Sending tissue across borders is an administrative and practical process as much as a medical one. Your hospital holds the blocks, so its permission and its release procedure come first. Ask the pathology department directly whether it releases slides and blocks to an overseas laboratory, what it requires in writing, and whether it keeps material for its own future testing. Do not assume release is routine.

Shipping is a second question. Diagnostic tissue is not an ordinary parcel, and the requirements depend on the carrier and the destination. Ask the reviewing laboratory how it expects material to be packed and labelled, and ask the courier what documentation it needs. Keep tracking details and a complete inventory of what was sent, so that everything can be returned or accounted for.

Timing is a question for the specific laboratory, not a general rule. Ask how long the review is expected to take once material arrives, whether additional tests would extend that, and how the report will be delivered. If your treatment decision is urgent, say so plainly and ask whether the review can be prioritised or whether treatment should proceed on the existing report. That is a clinical judgement for your treating team, and it may be the right answer even when a review is desirable.

How the review fits with molecular testing and staging

For many lung cancers, treatment now depends on molecular features of the tumour as well as its histological type. A pathology review may therefore include an assessment of whether the existing sample is sufficient for the molecular tests your treating team considers relevant. If the sample is small or was used up by earlier testing, the review may conclude that further tissue is needed. Whether to obtain more tissue, and how, is a decision for the treating clinicians.

The review does not replace staging. Staging draws on imaging, and sometimes on procedures that sample lymph nodes or other sites. A pathologist reviewing a lung biopsy cannot tell you the stage from that biopsy alone. When you approach a hospital in China, expect the team to want the imaging as well as the pathology, and expect staging to be revisited in light of everything available.

This is also where a records-based opinion can help before travel. A specialist can look at the pathology report, the imaging and the clinical summary and indicate what further information the team would need. That opinion is not a final treatment decision and does not guarantee acceptance; it helps you arrive with a coherent file rather than a folder of unconnected documents.

What the review cannot tell you

A pathology review describes tissue. It cannot tell you whether you are fit for surgery, whether a particular drug will work in your case, or what your outcome will be. Those questions belong to the treating clinicians, who consider the pathology alongside staging, your lung function, other medical conditions and your preferences. Be cautious of any service that presents a pathology opinion as a treatment decision.

A review also does not establish access to a particular therapy, clinical trial or hospital bed in China. Availability of specific tests, drugs and trial slots changes and must be confirmed with the named hospital. If a treatment depends on a molecular result, ask the treating team which tests they require, whether your existing material can provide them, and what happens if it cannot.

Finally, a review is a second opinion on the tissue, not a guarantee that the first report was wrong. Many reviews confirm the original diagnosis, and that is a legitimate outcome. The value lies in knowing that the diagnosis underpinning your plan has been examined with the specific treatment question in mind.

A practical next step

Start by gathering the original pathology report, any molecular reports and a short summary of your current diagnosis and question. An initial enquiry to ChinaSpecialistCare is free: the team checks what you have, identifies obvious gaps and suggests a relevant next step, which may be a pathology review, a specialist appointment or simply clarification of what the hospital will need. You do not need to buy a proxy consultation to make that first contact.

If you later want a records-based specialist opinion before travelling, that can be arranged separately, and the treating hospital in China still decides suitability and acceptance after seeing your full case. Send a brief summary first through the enquiry form, email or WhatsApp, and share detailed records only after the team confirms what is needed.

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Related treatment reference
  2. Tests and next steps for lung cancer - NHS
  3. Overview | Lung cancer: diagnosis and management | Guidance | NICE
  4. Diagnosis and staging | Lung cancer: diagnosis and management | Guidance | NICE
  5. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for
  6. The 7th lung cancer TNM classification and staging system: Review of the changes and implications - PMC

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.